Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Shelby Anderson, Ph.D.
Director of Drug Metabolism Services
Dr. Anderson has significant experience with the regulatory guidances on metabolites in safety testing (MIST) and clearance pathways (DDIs), metabolite profiling and identification, metabolic processes and mechanisms, excretion mass balance studies, the evaluation of ADME properties as relevant to drug discovery and development efforts, the clinical biopharmaceutics package, as well as regulatory interactions.

Dr. Anderson earned her Ph.D. in organic chemistry from Harvard University and completed a post-doctoral fellowship at Yale University.

Prior to joining Q2 Solutions in 2011, Dr. Anderson was a DMPK project leader at Eli Lilly, sitting on drug discovery and clinical project teams, and was the Biotransformation Group Leader, directing metabolite profiling and identification efforts across the development portfolio.  She started her career in DMPK as a discovery project leader at Pfizer.